Nanotechnology

A promising new paradigm for the control of pain

Krishnan V. Chakravarthy, Frank J. Boehm, Paul Christo

Research output: Contribution to journalReview article

Abstract

Objective. The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice. Study Design. Narrative review. Methods. The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings. Results. Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles. Conclusions. As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).

Original languageEnglish (US)
Pages (from-to)232-243
Number of pages12
JournalPain Medicine (United States)
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Nanotechnology
Acute Pain
Pain Management
Chronic Pain
Pain
Translational Medical Research
United States Food and Drug Administration
PubMed
Nanoparticles
Patient Care
Industry
Clinical Trials
Databases
Technology
Costs and Cost Analysis
Clinical Studies
Therapeutics

Keywords

  • Biotechnology
  • Chronic pain
  • Dendrimers
  • Diagnostics
  • Drug delivery
  • Nanomedicine
  • Nanoparticles
  • Nanotechnology
  • Quantum dots

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Nanotechnology : A promising new paradigm for the control of pain. / Chakravarthy, Krishnan V.; Boehm, Frank J.; Christo, Paul.

In: Pain Medicine (United States), Vol. 19, No. 2, 01.01.2018, p. 232-243.

Research output: Contribution to journalReview article

Chakravarthy, Krishnan V. ; Boehm, Frank J. ; Christo, Paul. / Nanotechnology : A promising new paradigm for the control of pain. In: Pain Medicine (United States). 2018 ; Vol. 19, No. 2. pp. 232-243.
@article{64cfd57a823042478417674da2e4376f,
title = "Nanotechnology: A promising new paradigm for the control of pain",
abstract = "Objective. The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice. Study Design. Narrative review. Methods. The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings. Results. Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles. Conclusions. As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).",
keywords = "Biotechnology, Chronic pain, Dendrimers, Diagnostics, Drug delivery, Nanomedicine, Nanoparticles, Nanotechnology, Quantum dots",
author = "Chakravarthy, {Krishnan V.} and Boehm, {Frank J.} and Paul Christo",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/pm/pnx131",
language = "English (US)",
volume = "19",
pages = "232--243",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Nanotechnology

T2 - A promising new paradigm for the control of pain

AU - Chakravarthy, Krishnan V.

AU - Boehm, Frank J.

AU - Christo, Paul

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective. The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice. Study Design. Narrative review. Methods. The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings. Results. Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles. Conclusions. As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).

AB - Objective. The objective of this article is to critically review both preclinical and clinical studies that focus on the use of nanotechnology for both acute and chronic pain management, surveying both diagnostic and therapeutic applications. The article also provides information on nanotechnology for pain practitioners, so that they may better understand how this technology works and how it may be applied to their day-to-day clinical practice. Study Design. Narrative review. Methods. The Pubmed NCBI and EMBASE databases were utilized to review published reports of in vivo and clinical studies that focus on using nanotechnology for pain management applications in both the acute and chronic pain settings. Results. Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications, and appropriate data were presented based on a critical analysis of those articles. Conclusions. As the development of nanomedical applications in acute and chronic pain management continues, medical practitioners should consider their growing potential to enhance the care of patients who are consistently living with pain. Current barriers to implementation include manufacturing scale-up for commercial viability, long-term nanoparticle toxicity considerations, and high cost for successful passage through clinical trials. These challenges will need to be overcome with ongoing translational research efforts in collaboration with industry and government bodies such as the Food and Drug Administration (FDA).

KW - Biotechnology

KW - Chronic pain

KW - Dendrimers

KW - Diagnostics

KW - Drug delivery

KW - Nanomedicine

KW - Nanoparticles

KW - Nanotechnology

KW - Quantum dots

UR - http://www.scopus.com/inward/record.url?scp=85047193815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047193815&partnerID=8YFLogxK

U2 - 10.1093/pm/pnx131

DO - 10.1093/pm/pnx131

M3 - Review article

VL - 19

SP - 232

EP - 243

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 2

ER -